6 results about "Levamisole" patented technology

The invention discloses an environment-friendly production process of levamisole ferulate and a harmful wastewater purification device, and relates to the technical field of wastewater treatment.The device comprises a sand filter tank and a sedimentation basin, the sand filter tank is connected with the sedimentation basin, a filter material layer is arranged in the sand filter tank, and a rotatable filter material treatment mechanism is arranged in the sand filter tank; the lower part of the filter material treatment mechanism extends into the filter material layer; in the running process of the sand filter tank, the filter material treatment mechanism is configured to rotate around the axis of the filter material treatment mechanism and shovel the filter material in the filter material layer into the filter material treatment mechanism, grinding and kneading attachments on the surface of the filter material, and then backfilling the treated filter material into the filter material layer. According to the sand filter, the grinding roller in the filter material treatment bin is matched with the grinding layer, sand grains are directly and strongly kneaded and rubbed in the equipment operation process, colloids, viscous substances and pigments adhered to the surface of a filter material are effectively stripped, the filter material layer is prevented from being hardened or forming mud balls, and therefore the operation cycle of the sand filter is remarkably prolonged.

The invention discloses a formula and a preparation method of a stomach-invigorating parasite-expelling tablet for livestock. The parasite expelling tablet is formed by compounding and tabletting parasite expelling core enteric particles A and stomach invigorating and relieving quick-release particles B. The particles A contain praziquantel and levamisole or salts thereof, and are coated with enteric materials, so that the parasite expelling activity is limited in gastric segment release and is quickly released in intestinal segment; the particles B contain a cortex meliae extract, a fructus quisqualis extract, pericarpium citri reticulatae, fried malt and fructus crataegi, are compounded with mucous membrane protection or adsorption stimulation components such as sodium alginate / pectin / montmorillonite and the like, and are subjected to post-treatment adsorption through essence, so that the taste covering stability is improved. The preparation method comprises the following steps: plant extraction, wet granulation in two ways, enteric coating of particles A, essence post-treatment of particles B, and compounding, lubricating and tabletting. According to the scheme, the insect expelling effect is guaranteed, gastrointestinal stimulation is reduced, the voluntary ingestion rate and administration compliance are improved, and the composition is suitable for dogs, cats and livestock to expel insects by oral administration.

The invention discloses a composite water-soluble vaccine adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. The adjuvant is based on a composite technology of a water-soluble component and a targeted delivery carrier, through a dual targeting effect of mannose modified beta-glucan, the uptake efficiency of dendritic cells on antigens is remarkably improved, and regulation and control on immune response are realized in cooperation with levamisole. The adjuvant has the characteristics of uniform particle size, excellent water solubility, good storage stability and the like, the immunological enhancement effect of the adjuvant is remarkably superior to that of a traditional adjuvant, and the adjuvant can be widely applied to research and development of vaccines for influenza, tuberculosis, tumor and the like, and has important clinical value and industrialization potential.

The application discloses a kind of composite water-soluble vaccine adjuvant and preparation method thereof, belong to biological medicine technical field.The adjuvant is based on the composite technology of water-soluble component and targeted delivery carrier, through the dual targeting effect of mannose modified beta-glucan, the uptake efficiency of dendritic cells to antigen is significantly improved, and the regulation of immune response is realized by synergistic levamisole.The adjuvant has the characteristics of uniform particle size, excellent water solubility, good storage stability, etc., and the immune enhancement effect is significantly better than traditional adjuvant, and can be widely used in the research and development of influenza, tuberculosis and tumor vaccines, has important clinical value and industrialization potential.

This invention relates to the fields of medicinal chemistry and biotechnology, and proposes a method for improving the resolution efficiency of drugs used to treat echinococcosis, comprising the following steps: Step 1: Praziquantel is reacted with a designed enzyme in a buffer solution containing Fe²⁺ for enzymatic reaction; Step 2: After removing the enzyme protein, the pH is adjusted to 1.0 for crystallization; Step 3: The praziquantel enzymatic reaction product detection solution is freeze-dried in a carbon dioxide incubator until the total amount of praziquantel and its derivatives is 350 mg / L, and then the pH is adjusted to 1.0 with 2 mol / L hydrochloric acid under ice bath conditions to obtain precipitated levamisole crystals. This invention achieves selective catalytic modification of dextrorotatory praziquantel using a genetically engineered specific enzyme while leaving levamisole almost unaffected, significantly improving the resolution efficiency of praziquantel.

This invention relates to the field of pharmaceutical technology, specifically to a perioperative neuroprotective anesthetic composition and its application for ischemic stroke. The composition comprises the active ingredient remimazolam or a pharmaceutically acceptable salt thereof, MCC950, TRO19622, levamisole or a pharmaceutically acceptable salt thereof, lipoic acid, and a pharmaceutically acceptable carrier, with each active ingredient formulated in a specific molar ratio. This composition combines stable and controllable anesthetic effects with multi-target synergistic neuroprotective effects, adapting to the entire perioperative anesthesia needs for ischemic stroke. Through upstream and downstream synergistic inhibition of mitochondrial damage and the NLRP3 pyroptosis pathway, dual regulation of perioperative sympathetic tone to stabilize cerebral perfusion, synergistic reduction of glutamate excitotoxicity, and enhancement of endogenous antioxidant defense, it comprehensively blocks the core links of perioperative ischemia-reperfusion brain injury, significantly reducing the risk of postoperative neurological deficits and cognitive impairment. It exhibits excellent circulatory and respiratory safety, rapid awakening without affecting early postoperative neurological function assessment.